Janar Sathananthan, Ole De Backer, and Michael Reardon dive into the newest findings on TAVR from the late-breaking ACURATE IDE trial.

Though X (formerly Twitter) was once a place many cardiologists found community and opportunity, many are jumping ship.

An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Host Shelley Wood hears some scientific session highlights from AHA President Keith Churchwell.

Written to offer advice where formal guidelines fall short, the document urges a balance between bleeding and ischemic risk.

The study was stopped early to allow all patients with advanced PAH the option for treatment with the activin signaling ...

Investigators saw more deaths in patients with severe TR after repeat mitral valve procedures; what to do about it is unclear ...